James Noble Net Worth & Insider Trades
James Noble - Director, Adaptimmune Therapeutics Plc
What is James Noble's Net Worth?
The current estimated net worth of Adaptimmune Therapeutics Plc's Director, James Noble, is estimated to be about $23.79M . James Noble owns about 0 unit of Adaptimmune Therapeutics Plc common stock. In the last 6 years at Adaptimmune Therapeutics Plc, James Noble has sold an estimated value of $6.07M worth.
What is James Noble's Past Insider Trading?
James Noble's largest sale order was 500,000 units , worth over $4.67M on June 2, 2020. In total, James Noble has made about 11 transactions over 6 years of their time at Adaptimmune Therapeutics Plc. James Noble usually trades in January, with the busiest year in 2020.
James Noble
Date Range: All Time
Ticker
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||
What is James Noble's' Mailing Address?
- Mailing address is 322 East Main Street Branford CT 06405 CT
Adaptimmune Therapeutics Plc Executive Compensation
Name |
Year
|
Salary
|
Option Awards
|
Other Earnings Plans or Compensations
|
Other Compensation
|
Total
|
|---|---|---|---|---|---|---|
| Adrian Rawcliffe | 2020 | $574,000 | $1,715,346 | $378,840 | $33,416 | $2,701,602 |
| Adrian Rawcliffe | 2019 | $500,481 | $1,427,399 | $177,251 | $49,912 | $2,155,042 |
| Adrian Rawcliffe | 2018 | $457,011 | $730,791 | $174,807 | $54,775 | $1,417,384 |
| Gavin Wood | 2020 | $337,065 | $990,268 | $166,847 | $73,731 | $1,567,911 |
| Helen Tayton-Martin | 2020 | $454,940 | $857,661 | $225,195 | $23,531 | $1,561,327 |
| Helen Tayton-Martin | 2019 | $435,949 | $766,900 | $137,324 | $30,491 | $1,370,664 |
| Helen Tayton-Martin | 2018 | $408,308 | $730,791 | $156,178 | $22,007 | $1,317,284 |
| William Bertrand | 2020 | $443,456 | $857,661 | $219,511 | $30,485 | $1,551,113 |
| William Bertrand | 2019 | $432,640 | $766,900 | $136,282 | $35,358 | $1,371,180 |
| William Bertrand | 2018 | $416,000 | $685,114 | $159,120 | $35,070 | $1,295,304 |
| John Lunger | 2020 | $400,000 | $857,661 | $198,000 | $31,802 | $1,487,463 |
| John Lunger | 2019 | $366,867 | $435,546 | $94,542 | $35,655 | $932,610 |
| John Lunger | 2018 | $316,958 | $602,909 | $92,948 | $35,07 | $1,047,885 |
| Michael Garone | 2020 | $217,000 | - | - | - | $217,000 |
| Michael Garone | 2019 | $206,500 | - | - | - | $206,500 |
| No matching records found | ||||||
Source: https://www.sec.gov/Archives/edgar/data/1621227/000110465921047833/tm212433-2_def14a.htm
What are Adaptimmune Therapeutics Plc's Past Insider Trades?
Adaptimmune Therapeutics Plc's most recent insider trade came on January 31, 2023 by Cintia Piccina who sold 11,890 units worth $22.23K . In the last 7 years, insiders at Adaptimmune Therapeutics Plc have sold an estimated value of $40.34M and bought an estimated value of $526.78M worth of shares. Insider trading is most common in January, with the busiest year in 2018. The most active traders at the company are Adrian Rawcliffe, Chief Executive Officer, John Lunger, Chief Patient Supply Officer, and William Charles Bertrand, Chief Operating Officer .
Adaptimmune Therapeutics PLC Insider Trades
Date Range: All Time
Insider Names
|
Type
|
Value
|
Price per Share
|
Shares
|
Filing Date
| ||
|---|---|---|---|---|---|---|---|
| No matching records found | |||||||